Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15344142 | 0.75 | ATM (0.47) | RECQLPOLBGAATSHRALDH1A1 | |
| SCHEMBL1830962 | 0.72 | RECQL (0.44) | RECQLPOLBGAATSHRMAPT | |
| SCHEMBL29403090 | 0.70 | PDGFRB (0.64) | RECQLPOLBGAATSHRALDH1A1 | |
| SCHEMBL993337 | 0.70 | PDGFRB (0.64) | RECQLPOLBGAATSHRALDH1A1 | |
| SCHEMBL1836103 | 0.70 | RECQL (0.54) | RECQLPOLBGAATSHRMAPT | |
| SCHEMBL2334136 | 0.68 | POLB (0.44) | RECQLPOLBGAATSHRMAPT | |
| SCHEMBL18691187 | 0.68 | ALDH1A1 (0.43) | RECQLPOLBGAATSHRMAPT | |
| SCHEMBL17285233 | 0.67 | ALDH1A1 (0.38) | RECQLPOLBGAATSHRMAPT | |
| SCHEMBL13283382 | 0.67 | RECQL (0.40) | RECQLPOLBGAATSHRMAPT | |
| SCHEMBL14994638 | 0.67 | PDGFRB (0.41) | RECQLPOLBGAAALDH1A1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | XPO1, XPOT, DDB1 | RECQL 162/4885POLB 736/4885GAA 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.